Position in PFE
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$15,350,577
+$978,795 QoQ
Shares Held
546,673
-5.3% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in PFE Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026M&G PLC holds $1,488,143,891 across 11 Drug Manufacturers - General names. PFE ranks #7 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
4,204,199 | $829,152,126 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
5,764,140 | $349,595,091 | |
| 3 | AMGN |
Amgen Inc
|
439,063 | $154,484,316 | |
| 4 | ABBV |
AbbVie Inc.
|
262,231 | $57,032,620 | |
| 5 | MRK |
Merck & Co., Inc.
|
298,044 | $35,851,712 | |
| 6 | JNJ |
Johnson & Johnson
|
76,011 | $18,580,128 | |
| 7 | PFE |
Pfizer Inc
This page
|
546,673 | $15,350,577 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
95,757 | $13,345,653 |
All Filings in PFE
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $15,350,577 | 546,673 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $14,371,782 | 577,180 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $13,924,412 | 546,484 | Shares | Defined | 2025-11-07 | |
| 2025-06-30 | $15,282,204 | 630,454 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $18,500,835 | 730,104 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $21,132,551 | 796,553 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $23,106,969 | 798,444 | Shares | Sole | 2024-10-31 | |
| 2024-06-30 | $22,759,575 | 813,423 | Shares | Sole | 2024-07-16 | |
| 2024-03-31 | $19,707,189 | 710,169 | Shares | Sole | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||